Levosimendan Stada (Levosimendan)

• Levosimendan is used in the management of acute heart failure and related low‑output states.
• Acute decompensated heart failure: improves cardiac output and reduces symptoms of congestion.
• Cardiogenic shock: provides inotropic support when conventional agents are insufficient.
• Post‑cardiac surgery low cardiac output syndrome: helps maintain hemodynamic stability during recovery.
• Severe chronic heart failure awaiting transplant: used as bridge therapy to improve functional status.

• Levosimendan binds to cardiac troponin C, increasing its affinity for calcium and thereby enhancing contractile force without raising intracellular calcium levels. Simultaneously, it opens ATP‑sensitive potassium channels in vascular smooth muscle, causing vasodilation and reducing after‑load, which together improve overall cardiac performance in heart‑failure patients.

Levosimendan may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Hypotension: mild to moderate drop in blood pressure, often transient.
• Headache: dull or throbbing pain, usually resolves without intervention.
• Nausea: occasional upset stomach, may be alleviated with anti‑emetics.
• Tachycardia: modest increase in heart rate, monitored during infusion.

Serious or Rare Side Effects

• Severe hypotension: profound blood pressure fall requiring vasopressor support.
• Ventricular arrhythmias: potentially life‑threatening rhythm disturbances.
• Myocardial ischemia: reduced coronary perfusion leading to chest discomfort.
• Allergic reactions: rash, pruritus, or anaphylaxis in susceptible individuals.

Levosimendan requires careful monitoring and specific precautions to ensure patient safety.

• Cardiovascular monitoring: continuous blood pressure and ECG observation during infusion.
• Renal function: assess renal impairment before initiation and adjust therapy as needed.
• Electrolyte balance: correct potassium and magnesium abnormalities to reduce arrhythmia risk.
• Concomitant vasodilators: use with caution as additive hypotensive effects may occur.
• Hypersensitivity: discontinue immediately if signs of allergic reaction appear.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Levosimendan can interact with several drug classes, influencing its safety and efficacy.

Major Interactions (Avoid)

• Potent vasodilators (e.g., nitroglycerin): may cause severe hypotension.
• Other inotropes (e.g., dopamine, dobutamine): increase risk of arrhythmias.
• Strong CYP450 inhibitors (e.g., ketoconazole): can raise plasma concentrations.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: may blunt desired hemodynamic response.
• Diuretics: can exacerbate electrolyte disturbances.
• ACE inhibitors or ARBs: additive hypotensive effect may require dose adjustment.